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Clopidogrel Versus Ticlopidine After
the Placement of Coronary Artery Stents
In a study published recently in JACC, Mueller et al. (1) compared
treatment with clopidogrel and aspirin to ticlopidine and aspirin in
patients undergoing coronary stent placement. Both drugs were
started after the procedure and continued for four weeks. Ticlo-
pidine was given as a 500-mg loading dose followed by 250 mg
twice daily thereafter; however, clopidogrel was given without
loading: 75 mg daily. The results suggested that clopidogrel was
inferior to ticlopidine in terms of cardiovascular mortality. In other
studies involving clopidogrel, a loading dose of 300 mg was given
initially followed by 75 mg daily thereafter (2,3). A loading dose of
300 mg of clopidogrel is needed in order to achieve timely platelet
inhibitory effect (4). The lack of clopidogrel loading clearly delays
the effect of clopidogrel and, therefore, may cause a higher
thrombotic stent occlusion (TSO) rate (the TSO rate was not
reported by Mueller et al.). Use of a clopidogrel loading dose in
this instance may show clopidogrel not to be inferior to ticlopidine
(3).
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REPLY
We fully agree with Dr. Rott that the lack of a loading dose of
clopidogrel is an important issue in interpreting our data. After
completion of our study, two major clinical trials, Clopidogrel for
the Reduction of Events During Observation (CREDO) (1) and
ISAR-REACT (2), were reported that highlight the need for a
loading dose of clopidogrel. In CREDO, the best clinical outcome
was seen in those patients who achieved the full antiplatelet effect
of clopidogrel at the time of intervention, which was 6 h after a
loading dose of 300 mg. Based on clinical observations (3) and ex
vivo analysis of platelet function (4), the ISAR-REACT trial used
an even higher loading dose of clopidogrel, 600 mg, which enables
the full antiplatelet effect of clopidogrel within 2 h (4). With this
loading scheme, the antithrombotic efficacy in patients undergoing
elective interventions could not be further improved even with
abciximab, as shown by the composite 30-day end point of death,
myocardial infarction, and urgent revascularization (2).
In light of these new findings, we cannot exclude that the results
of our trial, as well as those of other trials suggesting inferiority of
clopidogrel compared with ticlopidine (5), would have been
different had an appropriate loading dose been used. Notably, a
high loading dose may overcome the other potential explanation of
our findings, which is the interference of statins. Although the
issue has not been completely settled, preliminary reports indicate
that attenuation of the antiplatelet effect by statins is not detectable
after a 600-mg loading dose (6).
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Fast Food and Obesity in China
As Dr. DeMaria stated in his recent Editor’s Page (1), the
introduction of fast food in America undoubtedly contributed to
the increase in obesity. He also suggested that “the introduction of
fast food overseas has been accompanied by a similar increase in
obesity in these countries” (1). This is certainly true for China.
China swallows fast food at an even faster rate than ever.
According to the Financial Times (2), the success of Kentucky
Fried Chicken (KFC) and McDonald’s in China is the result of a
transformation of China’s lifestyles, which are becoming more
geared to speed and convenience. There is also some sense of
curiosity and faddishness on the part of Chinese youth toward
Western fast-food restaurants. There are now over 800 KFCs and
half as many McDonald’s in China (2).
China is now fighting obesity as is the rest of the world (3). In
Beijing, 27.8% of children surpass the standard weight guidelines
(4). By the end of 2000, the obesity rate of male students in Beijing
reached 15%, doubling that of 1990 and approaching that of
developed countries (4). Obese children grow up to be obese
adults. Currently, there are tens of millions of people suffering
from obesity in China; the number of diabetics is increasing by
3,000 a day; and that of hypertensive patients, who exceed 100
million, is rising at an annual rate of 2.5% (5). The latter is
undoubtedly the result of the high sodium content contained in
fast food.
There is a price that every developing country must pay for
modernization. However, let us hope that the price the Chinese
pay will not exceed the benefits derived from modernization (6).
Can we achieve a utopian stage in the 21st century in which the
modern Chinese retain their ancestral lean body weight while
enjoying the positive aspects of a modern Western lifestyle?
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